Document is current

Article History

Received: 23 February 2024

Accepted: 15 July 2024

First Online: 6 August 2024

Declarations

:

: Maite Ferrin has been attending ISBEA meetings in 2021, 2022 and 2023; she has been a member of the advisory board for Novartis in 2021 and Neuraxpharm International in 2023. Alexander Häge has been in the past 3 years a member of advisory board of / and/or speaker for Takeda and Medice. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties. James Swanson reported honoraria, consulting fees, and support for travel to and presentations at professional meetings by Medice, NLS, and Takeda; a patent for Pixel Averages for Auxological Assessment (PIXA); a patent pending for Prevention of Accumulated Tolerance for Stimulant Medication for Treatment of ADHD (PATSMTA); and previous but not current or recent support from grants and contracts for studies of treatment of attention-deficit/hyperactivity disorder. Kirstie H. T. W. Wong: None. Ralf W. Dittmann has received compensation for serving as consultant or speaker, or he or the institution he works for have received research support or royalties from the organizations or companies indicated: EU (FP7 Programme), US National Institute of Mental Health (NIMH), German Federal Ministry of Health/Regulatory Agency (BMG/BfArM), German Federal Ministry of Education and Research (BMBF), German Research Foundation (DFG), Volkswagen Foundation; Boehringer Ingelheim, Ferring, Janssen-Cilag, Lilly, Lundbeck, Otsuka, Servier, Shire, Sunovion/Takeda and Theravance. He was a former employee in clinical CNS research of Eli Lilly until Aug 2008, and owns Eli Lilly stock (small part of the respective annual salary). Since then, he has fully been affiliated with the Department of CAP, CIMH, Med Faculty Mannheim, University of Heidelberg, Germany. Tobias Banaschewski served in an advisory or consultancy role for eye level, Infectopharm, Lundbeck, Medice, Neurim Pharmaceuticals, Oberberg GmbH, Roche and Takeda. He received conference support or speaker’s fee by Janssen, Medice and Takeda. He received royalities from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press; the present work is unrelated to these relationships. David Coghill has been in the past 3 years a consultant to/member of advisory board of/and/or speaker for Takeda/Shire, Medice, Novartis, and Servier. He has received royalties from Oxford University press and Cambridge University press. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has received research support during this period from the Australian National Health and Medical Research Council and the Royal Children’s Hospital Foundation and funding for the current study from the European Commission. Paramala J. Santosh is the CEO and shareholder of HealthTracker Ltd and has received research funds from Newron Pharmaceuticals SpA, GWPharma, and Anavex Life Sciences Corp. Marcel Romanos: none. Emily Simonoff: none. Jan K Buitelaar has been in the past 3 years a consultant to/member of advisory board of/and/or speaker for Takeda, Roche, Medice, Angelini, Boehringer-Ingelheim, and Servier. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties.

: No ethics approval was required.

: Not applicipal.

: Not applicipal.